查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1973853

核子医学测量设备市场：按技术、产品类型、应用和最终用户划分－2026-2032年全球预测

Nuclear Medicine Instrumentation Market by Technology, Product Category, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，核医测量设备市场价值将达到 45.1 亿美元，到 2026 年将成长至 48.1 亿美元，到 2032 年将达到 72.5 亿美元，复合年增长率为 7.00%。

主要市场统计数据
基准年 2025 45.1亿美元
预计年份：2026年 48.1亿美元
预测年份 2032 72.5亿美元
复合年增长率 (%) 7.00%

对影响全球医疗保健服务中诊断和治疗创新的核医设备进行全面调查。

过去十年，核医仪器作为个人化诊断和治疗路径的基石，其重要性日益凸显，彻底改变了临床医师检测和治疗复杂疾病的方式。随着医疗服务提供者不断追求更高的精准度和更好的患者疗效，先进的影像技术和标靶放射性药物递送系统正处于医学创新的前沿。这项变革得益于检测器灵敏度、影像重建演算法以及影像与治疗功能整合的突破性进展。因此，核子医学如今在多学科医学范式中占据着至关重要的地位，为分子层面的生理过程提供了前所未有的深刻见解。

揭示驱动下一代核子医学设备模式转移：透过人工智慧分析、治疗诊断学和精准影像诊断的整合

核医仪器领域正因多种趋势的整合而重塑，这些趋势正在重新定义临床工作流程和研究前沿。其中最显着的是人工智慧 (AI) 和机器学习在影像撷取和解读的应用。自动影像分割和前所未有的示踪剂撷取定量分析正在简化决策流程，并减轻放射科医生的工作量。同时，治疗诊断一体化 (治疗诊断学) 方法的蓬勃发展，使得分子影像剂兼具治疗功能，为个人化医疗开闢了新的维度。如今，标靶放射性核种治疗可由诊断回馈迴路即时指导，从而在确保更高疗效的同时，最大限度地减少脱靶效应。

评估美国关税对核医设备供应链的连锁反应：製造成本与全球合作。

2025年，美国新实施的关税政策对整个核医设备生态系统产生了多方面的连锁反应。进口检测器、CT模组和专用组件关税的提高迫使製造商重新评估其全球供应链结构。为此，主要原始设备製造商（OEM）正在使其筹资策略多元化，并加快对本地组装和组件製造的投资。虽然这些调整旨在抵消进口成本的增加，但考虑到放射性物质和成像设备严格的安全标准，这些调整也可能为品管和合规性带来复杂性。

透过对核医设备市场进行全面的技术产品类型、应用和最终用户细分，得出策略性见解。

透过对技术采纳、产品类型差异化、临床应用和终端用户专业知识的深入了解，我们得以揭示塑造当今核医市场的复杂因素。包括PET/CT和SPECT/CT在内的混合影像平台的发展，凸显了系统向无缝整合功能和解剖数据的转变，从而满足肿瘤分期和神经系统评估的严格要求。同时，诊断设备和治疗设备之间界限的模糊化及其与放射性药物的整合，凸显了两种战略方向：一种侧重于图像采集和解读，另一种侧重于靶向放射性配体的给药以达到治疗目的。

为了解美洲、欧洲、中东和非洲以及亚太地区的区域趋势，并阐明核子医学影像的成长要素和扩散模式。

区域趋势导緻美洲、欧洲、中东和非洲以及亚太地区在技术采纳率和创新轨迹方面存在差异。在美洲，完善的医疗基础设施和充足的研究经费持续推动先进PET/CT和治疗性诊断平台的早期应用。虽然北美医疗机构已广泛采用整合成像疗法，但拉丁美洲市场对携带式SPECT/CT解决方案的兴趣日益浓厚，希望藉此扩大非都市区地区的诊断覆盖范围。

揭示核子医学设备领域主要全球参与者的竞争领导地位和合作创新策略。

核医学设备领域的主要企业正采取多元化策略，以保持竞争优势并促进技术应用。全球巨头企业不断透过有针对性的收购和策略性研究合作来拓展产品系列，并将先进的检测器技术和人工智慧软体整合到现有平台中。同时，中型区域企业则专注于新兴市场，致力于开发经济高效的模组化系统和在地化服务模式，从而开拓专业化的细分市场。

为产业领导者制定可操作的蓝图，以优化技术投资、建立策略伙伴关係并改善患者治疗效果。

为了掌握技术融合和监管变革带来的机会，产业领导者应优先投资于模组化、扩充性的平台，以满足诊断成像和治疗应用的需求。采用灵活的製造框架能够帮助企业加速部署下一代检测器和放射性药物，同时降低供应链中断的风险。组成跨职能团队，涵盖监管事务、临床专家和资料科学家，能够进一步简化产品核可流程，并提升市场应对力。

为确保资料的完整性和可靠性，详细阐述了严格的混合调查方法：将一手调查和二手调查与先进的分析技术结合。

本研究采用混合方法框架，结合了对临床医生、影像专家和采购经理的大量一手调查，以及涵盖同行评审期刊、监管资料库和专利申请的严谨二手调查。一手访谈和问卷调查直接提供了关于临床工作流程、采购标准和新兴需求的定性见解，而二手资讯来源提供了背景检验和趋势分析。透过对这些资讯进行三角验证，并进行交叉检验研讨会以协调不同观点并完善关键假设，从而确保了研究结果的稳健性。

本报告整合了关键研究成果，并提出了前瞻性的观点，为相关人员提供有关核子医学领域新兴趋势、机会和策略挑战的指南。

这项综合评估揭示了将决定核医设备未来发展的关键技术创新、监管因素和竞争动态。从混合成像系统和人工智慧驱动的分析技术的兴起，到治疗性诊断模式的出现，相关人员都有机会释放巨大的临床和营运价值。供应链调整和区域差异化所带来的成本进一步凸显了敏捷策略规划和稳健的伙伴关係生态系统的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：核子医学测量设备市场：依技术划分

  • 混合成像
    • PET/CT系统
    • SPECT/CT系统
  • 正子断层扫描
  • 单光子发射电脑断层扫描

第九章：核医测量设备市场（依产品类型）

  • 诊断设备
  • 医疗器材和放射性药物

第十章 核子医学测量设备市场：依应用领域划分

  • 心臟病学
  • 神经病学
  • 肿瘤学

第十一章 核子医学测量设备市场：依最终用户划分

  • 诊断影像中心
  • 医院
  • 研究机构

第十二章 核子医学测量设备市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 核子医学测量设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 核子医学测量设备市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国核子医学测量设备市场

第十六章：中国核子医学测量设备市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AMETEK Inc.
  • BJ Madan & Co
  • Berthold Technologies GmbH & Co.KG
  • Blue Earth Diagnostics
  • Bruker Corporation
  • Canon Medical Systems Corporation
  • Cardinal Health
  • COMECER SpA
  • Digirad
  • Exosens
  • GE Healthcare
  • Geebee International
  • Hidex Oy
  • Jubilant DraxImage, Inc.
  • Koninklijke Philips NV
  • Mirion Technologies, Inc.
  • Neusoft Medical Systems Co., Ltd.
  • Nucleonix Systems（P）Ltd.
  • Nucleuz Healthcare Pvt Ltd
  • NUVIATech Healthcare
  • OVIS Imaging Solutions
  • Radiation Monitoring Devices
  • Rotem Industries Ltd.
  • Siemens Healthineers AG
  • Spectrum Instrumentation
Product Code: MRR-546E6FBB3C4B

The Nuclear Medicine Instrumentation Market was valued at USD 4.51 billion in 2025 and is projected to grow to USD 4.81 billion in 2026, with a CAGR of 7.00%, reaching USD 7.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.51 billion
Estimated Year [2026] USD 4.81 billion
Forecast Year [2032] USD 7.25 billion
CAGR (%) 7.00%

A Comprehensive Exploration of Nuclear Medicine Instrumentation Shaping Diagnostic and Therapeutic Innovations in Healthcare Delivery Worldwide

Over the past decade, nuclear medicine instrumentation has increasingly become a linchpin in personalized diagnostic and therapeutic pathways, revolutionizing how clinicians detect and treat complex diseases. As healthcare providers strive to enhance precision and patient outcomes, advanced imaging modalities and targeted radiopharmaceutical delivery systems have emerged at the forefront of medical innovation. This transformation has been driven by breakthroughs in detector sensitivity, image reconstruction algorithms, and the convergence of imaging with therapeutic functions. Consequently, nuclear medicine now occupies a pivotal position within multidisciplinary care paradigms, offering unparalleled insights into physiological processes at the molecular level.

Transitioning from conventional gamma cameras to sophisticated hybrid platforms, the field has undergone a profound metamorphosis. Hybrid imaging systems that combine positron emission tomography with computed tomography or single photon emission computed tomography with CT have enabled seamless integration of anatomical and functional data. These developments have not only sharpened diagnostic confidence but also expanded the scope of applications across cardiology, neurology, and oncology. Moreover, the ongoing miniaturization of components, along with enhancements in data processing and radiopharmaceutical chemistry, continues to lower operational barriers, facilitating broader adoption across hospitals, diagnostic centers, and research institutions. This report embarks on a comprehensive exploration of these technological advances, regulatory evolutions, and market dynamics, laying a solid foundation for the in-depth analysis that follows.

Unveiling the Paradigm Shifts Driving Next Generation Nuclear Medicine Instrumentation Through Integration of AI Analytics Theranostics and Precision Imaging

The landscape of nuclear medicine instrumentation has been reshaped by converging trends that are redefining clinical workflows and research frontiers. Foremost among these is the integration of artificial intelligence and machine learning into image acquisition and interpretation. By automating image segmentation and quantifying tracer uptake with unprecedented precision, these algorithms are streamlining decision-making and alleviating radiologist workloads. Simultaneously, the surge in theranostic approaches-where molecular imaging agents double as therapeutic vehicles-has introduced a new dimension of personalized medicine. Targeted radionuclide therapies are now guided in real time by diagnostic feedback loops, ensuring higher efficacy and minimizing off-target effects.

Additionally, the emphasis on hybrid imaging systems has fostered cross-disciplinary collaborations, uniting experts in radiopharmaceutical chemistry, nuclear physics, and bioengineering. This collective effort has given rise to next-generation detectors utilizing novel scintillating materials and semiconductor technology, thereby elevating spatial resolution and sensitivity. The growing need for point-of-care diagnostics has also spurred the development of compact, portable SPECT/CT and PET/CT systems, facilitating decentralized clinical trials and improving access in remote or community-based settings. Collectively, these transformative shifts underscore a trajectory toward faster, smarter, and more patient-centric nuclear medicine practices.

Assessing the Ripple Effects of United States Tariffs on Nuclear Medicine Instrumentation Supply Chains Manufacturing Costs and Global Collaboration

In 2025, newly enacted United States tariff policies have generated multifaceted ripple effects across the nuclear medicine instrumentation ecosystem. Heightened duties on imported detectors, CT modules, and specialized components have compelled manufacturers to reassess global supply chain architectures. In response, leading original equipment manufacturers are diversifying their sourcing strategies and accelerating investments in local assembly and component fabrication. While these adjustments aim to offset increased import costs, they also introduce complexities in quality control and regulatory compliance, given the stringent safety standards governing radioactive materials and imaging devices.

Consequently, distributors and end users are recalibrating procurement plans to accommodate extended lead times and restructured pricing models. Some institutions have turned to consortia agreements to leverage collective purchasing power and negotiate more favorable terms with suppliers. At the same time, research partners are exploring alternative detector chemistries and modular designs that can be adapted to regional manufacturing capabilities. Through these adaptive measures, stakeholders are striving to maintain uninterrupted clinical operations and uphold high standards of patient care. This section examines how the tariff environment is catalyzing innovation in production processes, spurring supply chain resilience, and redefining international collaboration within the nuclear medicine sector.

Strategic Insights Emerging from Comprehensive Technology Product Category Application and End User Segmentation in Nuclear Medicine Instrumentation Markets

Insights drawn from technology adoption, product category differentiation, clinical application, and end-user specialization reveal the intricate drivers shaping today's nuclear medicine market. The evolution of hybrid imaging platforms, including PET/CT and SPECT/CT modalities, underscores a shift toward systems that seamlessly integrate functional and anatomical data, satisfying the exacting requirements of oncological staging and neurological assessment. Simultaneously, the delineation between diagnostic instruments and therapeutic instruments coupled with radiopharmaceuticals highlights a dual-track strategy: one focused on image acquisition and interpretation, the other on delivering targeted radioligands for treatment.

Clinical fields such as cardiology, neurology, and oncology are each benefitting uniquely from these advancements, with oncology driving the largest volume of tracer development and neurology increasingly leveraging imaging biomarkers for neurodegenerative conditions. Moreover, the dispersal of capabilities across diagnostic imaging centers, hospitals, and research institutions reflects a broadening user base that demands scalable solutions. Diagnostic imaging centers prioritize throughput and cost efficiency, while hospitals emphasize integrated workflows within electronic health record systems. Meanwhile, research institutes underpin innovation pipelines, validating novel radiotracers and pilot-testing miniaturized instrumentation. These layered insights inform strategic positioning and product development roadmaps for stakeholders operating across the full spectrum of nuclear medicine instrumentation.

Understanding Regional Dynamics in the Americas Europe Middle East Africa and Asia Pacific to Uncover Growth Drivers and Adoption Patterns in Nuclear Imaging

Regional dynamics are driving divergent adoption rates and innovation trajectories across the Americas, Europe Middle East Africa region, and the Asia Pacific. In the Americas, established healthcare infrastructures and substantial research funding continue to foster early adoption of advanced PET/CT and theranostic platforms. North American centers are increasingly deploying integrated imaging therapies at scale, while Latin American markets demonstrate growing interest in portable SPECT/CT solutions to expand diagnostic access beyond urban hubs.

Across Europe, Middle East, and Africa, regulatory harmonization efforts and pan-regional research collaborations are enabling cross-border clinical trials and enhanced data sharing. Western European nations maintain leadership in radiopharmaceutical development, whereas emerging markets in the Gulf cooperation council countries and Southern Africa are investing in modernizing nuclear infrastructure. Meanwhile, the Asia Pacific region is characterized by rapid expansion driven by rising noncommunicable disease prevalence and robust government initiatives. Countries such as China, Japan, and India are scaling up local manufacturing capabilities and forging strategic alliances with global technology providers. These regional contrasts provide invaluable guidance for tailoring market entry approaches and aligning stakeholder investments with localized healthcare priorities.

Revealing Competitive Leadership and Collaborative Innovation Strategies Adopted by Key Global Participants in Nuclear Medicine Instrumentation

Leading participants in the nuclear medicine instrumentation sector are adopting multifaceted strategies to maintain competitive advantage and stimulate technology diffusion. Major global corporations continue to expand their product portfolios through targeted acquisitions and strategic research partnerships, embedding advanced detector technologies and AI-powered software into existing platforms. Concurrently, mid-sized regional players are carving out specialized niches by focusing on cost-effective modular systems and localized service models that cater to emerging markets.

Innovation alliances between imaging equipment manufacturers and radiopharmaceutical developers are accelerating integrated theranostic solutions, enabling coordinated roll-outs of diagnostic agents and companion therapies. Furthermore, joint ventures with academic institutions are enhancing R&D pipelines, particularly in developing novel tracers for neuroinflammation and receptor-targeted oncology. By balancing broad geographic reach with deep domain expertise, these organizations are cultivating resilient supply chains, reinforcing after-sales support networks, and driving sustained customer loyalty. The synthesis of these competitive and collaborative initiatives shapes a dynamic landscape where continuous innovation and partnership agility are paramount.

Formulating Practical Roadmaps for Industry Leaders to Optimize Technology Investments Forge Strategic Partnerships and Enhance Patient Outcomes

To harness the opportunities presented by technological convergence and regulatory evolution, industry leaders should prioritize strategic investments in modular, scalable platforms that accommodate both diagnostic imaging and therapeutic applications. By adopting flexible manufacturing frameworks, organizations can mitigate supply chain disruptions while accelerating deployment of next-generation detectors and radiopharmaceuticals. Establishing cross-functional teams that include regulatory affairs, clinical specialists, and data scientists can further streamline product approval timelines and enhance market responsiveness.

Collaboration with academic research centers and contract development organizations will be essential for fast-tracking the discovery and validation of novel tracers. Equally important is the cultivation of a comprehensive digital ecosystem, integrating advanced analytics and cloud-based image management to support remote interpretations and decentralized clinical trials. Building robust training programs for technologists and clinicians will drive effective technology utilization and foster stakeholder confidence. Ultimately, aligning these initiatives with patient-centered value propositions and health economic models will ensure that investments translate into measurable clinical benefits and sustainable growth trajectories.

Detailing Rigorous Mixed Methodology Combining Primary Engagement Secondary Research and Advanced Analytical Techniques to Ensure Data Integrity and Reliability

This research employs a mixed-methodology framework, combining extensive primary engagements with clinicians, imaging specialists, and procurement executives with rigorous secondary research across peer-reviewed journals, regulatory databases, and patent filings. Primary interviews and surveys yield firsthand qualitative insights into clinical workflows, purchasing criteria, and emerging needs, while secondary data sources provide contextual validation and trend analysis. Triangulation of these inputs ensures robustness, with cross-verification workshops conducted to reconcile divergent perspectives and refine key assumptions.

Quantitative analysis includes benchmarking component lifecycles, pricing variances, and throughput metrics, supported by statistical modeling to identify correlation patterns and technology adoption curves. A systematic review of regulatory pathways and reimbursement policies informs the risk assessment of market entry scenarios. Finally, iterative expert validation sessions with academic and industry advisory panels serve to stress-test the findings and calibrate strategic recommendations. This methodological rigor guarantees that the conclusions drawn are both actionable and reflective of real-world dynamics in the nuclear medicine instrumentation landscape.

Synthesizing Key Findings into Forward Looking Perspective Guiding Stakeholders on Emerging Trends Opportunities and Strategic Imperatives in Nuclear Medicine

This comprehensive assessment has illuminated the critical technological innovations, regulatory factors, and competitive dynamics that are defining the future of nuclear medicine instrumentation. From the ascendancy of hybrid imaging systems and AI-driven analytics to the emergence of theranostic paradigms, stakeholders are positioned to unlock significant clinical and operational value. Tariff-induced supply chain adaptations and regional differentiation further underscore the necessity for agile strategic planning and robust partnership ecosystems.

Looking ahead, the convergence of digital health platforms, precision radiopharmaceuticals, and decentralized diagnostic capabilities will continue to drive differentiation. Organizations that integrate cross-disciplinary expertise, prioritize patient-centric workflows, and commit to ongoing innovation will lead the next wave of growth. By synthesizing the insights presented herein, decision makers can confidently navigate emerging challenges, seize value creation opportunities, and advance the standard of care in nuclear medicine.

In summary, the trajectory of nuclear medicine instrumentation is characterized by rapid evolution and multifaceted opportunity. The strategic imperatives outlined in this report offer a clear roadmap for stakeholders seeking to translate cutting-edge science into tangible healthcare impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nuclear Medicine Instrumentation Market, by Technology

  • 8.1. Hybrid Imaging
    • 8.1.1. PET/CT Systems
    • 8.1.2. SPECT/CT Systems
  • 8.2. Positron Emission Tomography
  • 8.3. Single Photon Emission Computed Tomography

9. Nuclear Medicine Instrumentation Market, by Product Category

  • 9.1. Diagnostic Instruments
  • 9.2. Therapeutic Instruments & Radiopharmaceuticals

10. Nuclear Medicine Instrumentation Market, by Application

  • 10.1. Cardiology
  • 10.2. Neurology
  • 10.3. Oncology

11. Nuclear Medicine Instrumentation Market, by End User

  • 11.1. Diagnostic Imaging Centers
  • 11.2. Hospitals
  • 11.3. Research Institutes

12. Nuclear Medicine Instrumentation Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Nuclear Medicine Instrumentation Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Nuclear Medicine Instrumentation Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Nuclear Medicine Instrumentation Market

16. China Nuclear Medicine Instrumentation Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AMETEK Inc.
  • 17.6. B J Madan & Co
  • 17.7. Berthold Technologies GmbH & Co.KG
  • 17.8. Blue Earth Diagnostics
  • 17.9. Bruker Corporation
  • 17.10. Canon Medical Systems Corporation
  • 17.11. Cardinal Health
  • 17.12. COMECER SpA
  • 17.13. Digirad
  • 17.14. Exosens
  • 17.15. GE Healthcare
  • 17.16. Geebee International
  • 17.17. Hidex Oy
  • 17.18. Jubilant DraxImage, Inc.
  • 17.19. Koninklijke Philips N.V.
  • 17.20. Mirion Technologies, Inc.
  • 17.21. Neusoft Medical Systems Co., Ltd.
  • 17.22. Nucleonix Systems (P) Ltd.
  • 17.23. Nucleuz Healthcare Pvt Ltd
  • 17.24. NUVIATech Healthcare
  • 17.25. OVIS Imaging Solutions
  • 17.26. Radiation Monitoring Devices
  • 17.27. Rotem Industries Ltd.
  • 17.28. Siemens Healthineers AG
  • 17.29. Spectrum Instrumentation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PET/CT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PET/CT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PET/CT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY SPECT/CT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY SPECT/CT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY SPECT/CT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY DIAGNOSTIC INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY DIAGNOSTIC INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY DIAGNOSTIC INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY THERAPEUTIC INSTRUMENTS & RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY THERAPEUTIC INSTRUMENTS & RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY THERAPEUTIC INSTRUMENTS & RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. GCC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. GCC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 105. GCC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. GCC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. G7 NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. G7 NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 123. G7 NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. G7 NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. NATO NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. NATO NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 129. NATO NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. NATO NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)